Symbols / ATHE $5.23 +16.89% Alterity Therapeutics Limited
ATHE Chart
About
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Fundamentals
Scroll to Statements| Market Cap | 98.80M | Enterprise Value | 48.56B | Income | -14.59M | Sales | 6.64M | Book/sh | 2.15 | Cash/sh | 0.01 |
| Dividend Yield | — | Payout | 0.00% | Employees | 9 | IPO | — | P/E | — | Forward P/E | -13.21 |
| PEG | — | P/S | 14.89 | P/B | 2.43 | P/C | — | EV/EBITDA | -2767.08 | EV/Sales | 7317.80 |
| Quick Ratio | 21.68 | Current Ratio | 21.98 | Debt/Eq | 0.18 | LT Debt/Eq | — | EPS (ttm) | -0.60 | EPS next Y | -0.40 |
| EPS Growth | — | Revenue Growth | 74.60% | Earnings | 2015-08-25 | ROA | -32.54% | ROE | -47.02% | ROIC | — |
| Gross Margin | 97.55% | Oper. Margin | -3.73% | Profit Margin | -219.85% | Shs Outstand | 18.13M | Shs Float | 8.31B | Short Float | 0.13% |
| Short Ratio | 1.92 | Short Interest | — | 52W High | 7.00 | 52W Low | 2.66 | Beta | -0.07 | Avg Volume | 13.38K |
| Volume | 108.81K | Target Price | $11.00 | Recom | None | Prev Close | $4.47 | Price | $5.22 | Change | 16.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$5.09
Latest analyst target
3. DCF / Fair value
$-10.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.09
Low
$10.00
High
$12.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | init | Canaccord Genuity | — → Speculative Buy | — |
| 2025-01-30 | main | Maxim Group | Buy → Buy | $12 |
| 2024-12-12 | init | Maxim Group | — → Buy | $8 |
| 2024-03-07 | reit | Benchmark | Speculative Buy → Speculative Buy | $4 |
| 2023-06-05 | main | Ladenburg Thalmann | Buy → Buy | $10 |
- [6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K - Stock Titan Mon, 20 Apr 2026 10
- Alterity brings in ex-Lilly, Teva executive ahead of Phase 3 push - Stock Titan Fri, 17 Apr 2026 11
- Meet the team who treats injured cowboys at the stock show - KUSA.com hu, 22 Jan 2026 08
- Rare disease drug data lands late-breaker slot at neurology meeting - Stock Titan hu, 16 Apr 2026 11
- No approved treatment for Multiple System Atrophy: Alterity webcast April 28 - Stock Titan Wed, 15 Apr 2026 11
- Alterity Therapeutics (ATHE) CEO details substantial share and option stakes - Stock Titan Wed, 15 Apr 2026 23
- Biotech leader Ann Cunningham joins Alterity Therapeutics (NASDAQ: ATHE) board - Stock Titan Fri, 17 Apr 2026 10
- Late-breaker ATH434 MSA results at AAN 2026 for Alterity (ATHE) - Stock Titan hu, 16 Apr 2026 10
- Alterity Therapeutics (NASDAQ: ATHE) hosts KOL event on ATH434 and MSA - Stock Titan Wed, 15 Apr 2026 10
- FDA feedback moves Alterity's atrophy drug toward Phase 3 - Stock Titan Mon, 30 Mar 2026 07
- CEO to share late-stage trial lessons at Bell Potter healthcare summit - Stock Titan Mon, 09 Mar 2026 07
- Director in Alterity Therapeutics (ATHE) reports multi-million share and option holdings - Stock Titan Fri, 10 Apr 2026 12
- CFO of Alterity Therapeutics (ATHE) details indirect shares and options in Form 3 - Stock Titan Fri, 10 Apr 2026 02
- Aiming for first MSA therapy, Alterity targets $2.4B opportunity - Stock Titan Wed, 21 Jan 2026 08
- Alterity Therapeutics (ATHE) director reports significant option holdings - Stock Titan Fri, 10 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
12.33
-36.43%
|
19.40
+35.04%
|
14.37
-5.08%
|
15.14
|
| Research And Development |
|
14.40
-22.74%
|
18.64
+41.26%
|
13.20
-10.49%
|
14.75
|
| Selling General And Administration |
|
5.34
+15.55%
|
4.62
-6.65%
|
4.95
-9.26%
|
5.46
|
| General And Administrative Expense |
|
5.34
+15.55%
|
4.62
-6.65%
|
4.95
-9.26%
|
5.46
|
| Salaries And Wages |
|
2.03
+44.98%
|
1.40
-26.16%
|
1.89
-14.41%
|
2.21
|
| Other Gand A |
|
2.77
+8.52%
|
2.55
+12.32%
|
2.27
-9.62%
|
2.51
|
| Other Operating Expenses |
|
-2.12
-40484.36%
|
0.01
-80.81%
|
0.03
+106.03%
|
-0.45
|
| Total Expenses |
|
12.33
-36.43%
|
19.40
+35.04%
|
14.37
-5.08%
|
15.14
|
| Operating Income |
|
-12.33
+36.43%
|
-19.40
-35.04%
|
-14.37
+5.08%
|
-15.14
|
| EBITDA |
|
-12.19
+36.67%
|
-19.25
-34.97%
|
-14.27
+5.42%
|
-15.08
|
| Normalized EBITDA |
|
-12.13
+37.86%
|
-19.52
-28.39%
|
-15.20
+14.63%
|
-17.81
|
| Reconciled Depreciation |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| EBIT |
|
-12.33
+36.43%
|
-19.40
-35.04%
|
-14.37
+5.08%
|
-15.14
|
| Total Unusual Items |
|
-0.07
-125.70%
|
0.26
-72.06%
|
0.93
-65.66%
|
2.72
|
| Total Unusual Items Excluding Goodwill |
|
-0.07
-125.70%
|
0.26
-72.06%
|
0.93
-65.66%
|
2.72
|
| Net Income |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Pretax Income |
|
-12.08
+36.68%
|
-19.08
-39.23%
|
-13.70
-7.24%
|
-12.78
|
| Net Non Operating Interest Income Expense |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Net Interest Income |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Interest Income Non Operating |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Interest Income |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Other Income Expense |
|
-0.19
-440.36%
|
0.06
-91.30%
|
0.65
-72.44%
|
2.36
|
| Other Non Operating Income Expenses |
|
-0.13
+38.78%
|
-0.20
+28.22%
|
-0.29
+21.83%
|
-0.36
|
| Gain On Sale Of Security |
|
-0.07
-125.70%
|
0.26
-72.06%
|
0.93
-65.66%
|
2.72
|
| Tax Provision |
|
0.07
+47.66%
|
0.05
-55.88%
|
0.10
+49.21%
|
0.07
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.02
-125.70%
|
0.08
-72.06%
|
0.28
-65.66%
|
0.82
|
| Net Income Including Noncontrolling Interests |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Net Income From Continuing And Discontinued Operation |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Net Income Continuous Operations |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Normalized Income |
|
-12.10
+37.32%
|
-19.31
-33.51%
|
-14.46
+1.98%
|
-14.75
|
| Net Income Common Stockholders |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Diluted EPS |
|
-1.14
+63.46%
|
-3.12
-447.37%
|
-0.57
+82.08%
|
-3.18
|
| Basic EPS |
|
-1.14
+63.46%
|
-3.12
-447.37%
|
-0.57
+82.08%
|
-3.18
|
| Basic Average Shares |
|
10.66
+75.31%
|
6.08
-74.95%
|
24.28
+505.45%
|
4.01
|
| Diluted Average Shares |
|
10.66
+75.31%
|
6.08
-74.95%
|
24.28
+505.45%
|
4.01
|
| Diluted NI Availto Com Stockholders |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Depreciation Amortization Depletion Income Statement |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation And Amortization In Income Statement |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation Income Statement |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Insurance And Claims |
|
0.55
-18.75%
|
0.68
-6.31%
|
0.72
+10.02%
|
0.66
|
| Other Taxes |
|
-5.44
-35.32%
|
-4.02
-2.68%
|
-3.91
+16.17%
|
-4.67
|
| Rent And Landing Fees |
|
—
|
—
|
0.07
-13.48%
|
0.08
|
| Rent Expense Supplemental |
|
—
|
—
|
0.07
-13.48%
|
0.08
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets |
|
46.03
+139.42%
|
19.22
-29.63%
|
27.32
-33.96%
|
41.36
|
| Current Assets |
|
45.87
+140.96%
|
19.04
-29.62%
|
27.05
-34.26%
|
41.14
|
| Cash Cash Equivalents And Short Term Investments |
|
40.66
+221.69%
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
|
| Cash And Cash Equivalents |
|
33.16
+162.35%
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
|
| Other Short Term Investments |
|
7.50
|
—
|
—
|
—
|
| Receivables |
|
3.94
-2.57%
|
4.04
-53.36%
|
8.67
+83.39%
|
4.73
|
| Accounts Receivable |
|
—
|
0.00
-100.00%
|
0.07
|
0.00
|
| Taxes Receivable |
|
3.94
-2.57%
|
4.04
-53.00%
|
8.60
+81.99%
|
4.73
|
| Accrued Interest Receivable |
|
0.00
-100.00%
|
0.00
-76.07%
|
0.00
+3544.44%
|
0.00
|
| Prepaid Assets |
|
1.23
-46.75%
|
2.32
-9.88%
|
2.57
+60.42%
|
1.60
|
| Other Current Assets |
|
0.04
+2.82%
|
0.04
+2.27%
|
0.04
+288.62%
|
0.01
|
| Total Non Current Assets |
|
0.16
-16.97%
|
0.19
-30.49%
|
0.27
+23.04%
|
0.22
|
| Net PPE |
|
0.16
-16.97%
|
0.19
-30.49%
|
0.27
+23.04%
|
0.22
|
| Gross PPE |
|
0.16
-16.97%
|
0.19
-74.36%
|
0.73
-0.58%
|
0.73
|
| Accumulated Depreciation |
|
—
|
-0.43
+6.03%
|
-0.46
+10.61%
|
-0.51
|
| Other Properties |
|
0.16
-16.97%
|
0.19
-74.36%
|
0.73
-0.58%
|
0.73
|
| Total Liabilities Net Minority Interest |
|
3.62
-33.22%
|
5.43
+20.44%
|
4.50
-23.57%
|
5.89
|
| Current Liabilities |
|
3.53
-34.22%
|
5.37
+22.63%
|
4.38
-24.71%
|
5.82
|
| Payables And Accrued Expenses |
|
2.59
-44.09%
|
4.64
+30.75%
|
3.55
-30.57%
|
5.11
|
| Payables |
|
0.57
-6.17%
|
0.61
-65.60%
|
1.78
-65.18%
|
5.11
|
| Accounts Payable |
|
0.54
-7.38%
|
0.58
-66.14%
|
1.72
-66.22%
|
5.08
|
| Other Payable |
|
0.02
+33.41%
|
0.01
-57.45%
|
0.03
-41.14%
|
0.06
|
| Current Accrued Expenses |
|
2.02
-49.86%
|
4.02
+127.67%
|
1.77
-25.09%
|
2.36
|
| Employee Benefits |
|
—
|
0.00
-100.00%
|
0.02
+41.81%
|
0.01
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.88
+65.05%
|
0.53
-27.22%
|
0.73
+11.11%
|
0.66
|
| Total Tax Payable |
|
0.02
+1.78%
|
0.02
-42.73%
|
0.03
+3.74%
|
0.03
|
| Current Debt And Capital Lease Obligation |
|
0.07
-37.54%
|
0.11
-0.04%
|
0.11
+85.97%
|
0.06
|
| Current Capital Lease Obligation |
|
0.07
-37.54%
|
0.11
-0.04%
|
0.11
+85.97%
|
0.06
|
| Other Current Liabilities |
|
0.00
-99.86%
|
0.10
|
—
|
-0.03
|
| Total Non Current Liabilities Net Minority Interest |
|
0.09
+70.56%
|
0.05
-57.69%
|
0.12
+66.70%
|
0.07
|
| Long Term Debt And Capital Lease Obligation |
|
0.09
+70.56%
|
0.05
-49.70%
|
0.10
+72.42%
|
0.06
|
| Long Term Capital Lease Obligation |
|
0.09
+70.56%
|
0.05
-49.70%
|
0.10
+72.42%
|
0.06
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
—
|
0.00
-100.00%
|
0.02
|
—
|
| Stockholders Equity |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Common Stock Equity |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Capital Stock |
|
262.95
+17.83%
|
223.15
+4.29%
|
213.97
+0.09%
|
213.79
|
| Common Stock |
|
262.95
+17.83%
|
223.15
+4.29%
|
213.97
+0.09%
|
213.79
|
| Share Issued |
|
9,127.37
+74.02%
|
5,245.12
+114.97%
|
2,439.90
+1.37%
|
2,406.87
|
| Ordinary Shares Number |
|
9,127.37
+74.02%
|
5,245.12
+114.97%
|
2,439.90
+1.37%
|
2,406.87
|
| Retained Earnings |
|
-225.89
-5.48%
|
-214.16
-9.75%
|
-195.13
-7.28%
|
-181.88
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
—
|
3.57
|
| Total Equity Gross Minority Interest |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Total Capitalization |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Working Capital |
|
42.34
+209.86%
|
13.66
-39.72%
|
22.67
-35.83%
|
35.32
|
| Invested Capital |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Total Debt |
|
0.16
-2.26%
|
0.16
-24.40%
|
0.21
+79.07%
|
0.12
|
| Capital Lease Obligations |
|
0.16
-2.26%
|
0.16
-24.40%
|
0.21
+79.07%
|
0.12
|
| Net Tangible Assets |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Tangible Book Value |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Other Equity Interest |
|
5.34
+11.15%
|
4.81
+20.99%
|
3.97
+11.40%
|
3.57
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-11.45
+9.16%
|
-12.61
+37.08%
|
-20.04
-62.40%
|
-12.34
|
| Cash Flow From Continuing Operating Activities |
|
-11.45
+9.16%
|
-12.61
+37.08%
|
-20.04
-62.40%
|
-12.34
|
| Net Income From Continuing Operations |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Depreciation Amortization Depletion |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation And Amortization |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Other Non Cash Items |
|
0.45
|
—
|
—
|
0.00
|
| Stock Based Compensation |
|
0.98
+11.11%
|
0.88
-8.75%
|
0.97
-35.82%
|
1.51
|
| Asset Impairment Charge |
|
0.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Operating Gains Losses |
|
-0.26
+0.66%
|
-0.26
+71.54%
|
-0.92
+67.39%
|
-2.81
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.26
+0.66%
|
-0.26
+71.54%
|
-0.92
+67.39%
|
-2.81
|
| Change In Working Capital |
|
-0.61
-110.67%
|
5.75
+189.96%
|
-6.39
-462.49%
|
1.76
|
| Change In Receivables |
|
0.10
-97.75%
|
4.62
+217.35%
|
-3.94
-780.16%
|
-0.45
|
| Change In Payables And Accrued Expense |
|
-2.04
-285.48%
|
1.10
+170.62%
|
-1.56
-159.94%
|
2.60
|
| Change In Payable |
|
-2.04
-285.48%
|
1.10
+170.62%
|
-1.56
-159.94%
|
2.60
|
| Change In Other Working Capital |
|
0.35
+258.35%
|
-0.22
-377.06%
|
0.08
-35.97%
|
0.12
|
| Change In Other Current Assets |
|
1.08
+327.44%
|
0.25
+126.13%
|
-0.97
-87.57%
|
-0.52
|
| Change In Other Current Liabilities |
|
-0.10
-736.71%
|
-0.01
|
0.00
|
0.00
|
| Investing Cash Flow |
|
-7.50
-130973.05%
|
-0.01
+84.31%
|
-0.04
+59.10%
|
-0.09
|
| Cash Flow From Continuing Investing Activities |
|
-7.50
-130973.05%
|
-0.01
+84.31%
|
-0.04
+59.10%
|
-0.09
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.01
+21.73%
|
-0.01
+91.80%
|
-0.09
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.01
+21.73%
|
-0.01
+91.80%
|
-0.09
|
| Capital Expenditure |
|
—
|
-0.01
+21.73%
|
-0.01
+91.80%
|
-0.09
|
| Net Investment Purchase And Sale |
|
-7.50
|
0.00
|
0.00
|
—
|
| Purchase Of Investment |
|
-7.50
|
0.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
-0.03
|
—
|
| Financing Cash Flow |
|
39.67
+330.43%
|
9.22
+7312.17%
|
0.12
-99.24%
|
16.30
|
| Cash Flow From Continuing Financing Activities |
|
39.67
+330.43%
|
9.22
+7312.17%
|
0.12
-99.24%
|
16.30
|
| Net Issuance Payments Of Debt |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Repayment Of Debt |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Long Term Debt Payments |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Net Long Term Debt Issuance |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Net Common Stock Issuance |
|
42.57
+319.64%
|
10.14
+3103.50%
|
0.32
-98.16%
|
17.18
|
| Net Other Financing Charges |
|
-2.77
-202.19%
|
-0.92
-593.30%
|
-0.13
+84.18%
|
-0.84
|
| Changes In Cash |
|
20.72
+710.21%
|
-3.40
+82.98%
|
-19.95
-614.37%
|
3.88
|
| Effect Of Exchange Rate Changes |
|
-0.20
-176.19%
|
0.26
-71.54%
|
0.91
-67.48%
|
2.81
|
| Beginning Cash Position |
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
+23.80%
|
28.12
|
| End Cash Position |
|
33.16
+162.35%
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
|
| Free Cash Flow |
|
-11.45
+9.20%
|
-12.61
+37.08%
|
-20.04
-61.29%
|
-12.43
|
| Cash Flowsfromusedin Operating Activities Direct |
|
-11.45
+9.16%
|
-12.61
+37.08%
|
-20.04
-62.40%
|
-12.34
|
| Classesof Cash Payments |
|
-17.53
+18.29%
|
-21.45
-7.00%
|
-20.05
-18.49%
|
-16.92
|
| Classesof Cash Receiptsfrom Operating Activities |
|
5.63
-34.41%
|
8.58
|
—
|
4.58
|
| Common Stock Issuance |
|
42.57
+319.64%
|
10.14
+3103.50%
|
0.32
-98.16%
|
17.18
|
| Interest Paid Direct |
|
0.00
+100.00%
|
-0.01
-58.09%
|
-0.00
-99.78%
|
-0.00
|
| Interest Received Direct |
|
0.45
+65.86%
|
0.27
+1603.22%
|
0.02
+473.43%
|
0.00
|
| Issuance Of Capital Stock |
|
42.57
+319.64%
|
10.14
+3103.50%
|
0.32
-98.16%
|
17.18
|
| Other Cash Receiptsfrom Operating Activities |
|
—
|
—
|
—
|
0.45
|
| Paymentsto Suppliersfor Goodsand Services |
|
-17.46
+18.39%
|
-21.39
-7.27%
|
-19.94
-18.18%
|
-16.88
|
| Receiptsfrom Government Grants |
|
—
|
—
|
0.00
-100.00%
|
0.45
|
| Taxes Refund Paid Direct |
|
5.56
-34.77%
|
8.53
+8340.90%
|
-0.10
-102.53%
|
4.08
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|